Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This activation raises intracellular cAMP, causing aquaporin‑2 water channels to move to the cell surface, which increases water reabsorption and concentrates the urine, reducing urine volume.

The dose of Minirin is individualized and determined by a qualified prescriber based on the patient’s age, weight, clinical condition, and response to therapy. Healthcare professionals adjust the amount and frequency to achieve the desired antidiuretic effect while monitoring safety parameters.

Safety data for desmopressin acetate during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Minirin.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The main alternative to desmopressin nasal spray is synthetic vasopressin (pitressin) administered intravenously or subcutaneously. Desmopressin offers a longer duration of action, higher V2‑receptor selectivity, and convenient nasal administration, which can improve adherence compared with injectable vasopressin that requires clinical supervision.

Minirin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the nasal spray bottle tightly closed when not in use, and avoid exposing it to extreme temperatures or humidity, which could affect potency.

Minirin is delivered as a metered‑dose nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently. The recommended number of sprays per dose is determined by the prescriber.

The most critical safety concerns involve water retention leading to hyponatremia, which can progress to seizures, coma, or even death if not recognized promptly. Severe hyponatremia, allergic reactions, and nasal septum perforation with long‑term use are also considered serious adverse events.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin acetate, those with existing hyponatremia, severe renal impairment, or uncontrolled hypertension. It should also be avoided in individuals who cannot monitor fluid balance adequately, as the risk of water intoxication would be heightened.